A Study of Oraxol in Subjects With Cutaneous Angiosarcoma
Status:
Active, not recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This is a non-blinded, multi-center, open-label, phase 2 study to evaluate the activity,
safety, and tolerability of Oraxol in subjects with cutaneous angiosarcoma.